_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
My Account
BSE Live
Feb 26, 16:00Prev. Close
331.90
Open Price
333.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 26, 15:59Prev. Close
332.05
Open Price
325.00
Bid Price (Qty.)
334.75 (1055)
Offer Price (Qty.)
0.00 (0)
| Quarterly Results of Unichem Laboratories (in Rs. Cr.) | Dec '20 | Sep '20 | Jun '20 | Mar '20 | Dec '19 | |
| Net Sales/Income from operations | 311.18 | 310.93 | 240.77 | 216.07 | 231.20 | |
| Other Operating Income | -- | -- | -- | -- | -- | |
| Total Income From Operations | 311.18 | 310.93 | 240.77 | 216.07 | 231.20 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 108.17 | 127.61 | 107.87 | 86.31 | 110.92 | |
| Purchase of Traded Goods | 0.16 | 0.27 | 0.05 | 0.38 | 0.09 | |
| Increase/Decrease in Stocks | 17.67 | -6.30 | 1.12 | -6.65 | -14.75 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 60.13 | 56.85 | 59.56 | 53.35 | 50.82 | |
| depreciat | 18.75 | 18.93 | 18.31 | 19.11 | 17.26 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 93.40 | 88.66 | 79.97 | 93.65 | 109.82 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 12.89 | 24.91 | -26.12 | -30.09 | -42.96 | |
| Other Income | 13.32 | 10.41 | 18.73 | 19.13 | 23.01 | |
| P/L Before Int., Excpt. Items & Tax | 26.22 | 35.32 | -7.39 | -10.96 | -19.95 | |
| Interest | 0.61 | 0.16 | 0.16 | 0.59 | 0.42 | |
| P/L Before Exceptional Items & Tax | 25.61 | 35.16 | -7.55 | -11.54 | -20.37 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 25.61 | 35.16 | -7.55 | -11.54 | -20.37 | |
| Tax | -4.82 | 4.82 | -- | 0.00 | -- | |
| P/L After Tax from Ordinary Activities | 30.43 | 30.34 | -7.55 | -11.55 | -20.37 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 30.43 | 30.34 | -7.55 | -11.55 | -20.37 | |
| Equity Share Capital | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 4.32 | 4.31 | -1.07 | -1.65 | -2.89 | |
| Diluted EPS | 4.32 | 4.31 | -1.07 | -1.65 | -2.89 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 4.32 | 4.31 | -1.07 | -1.65 | -2.89 | |
| Diluted EPS. | 4.32 | 4.31 | -1.07 | -1.65 | -2.89 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
19.02.2021
Unichem Laboratories share price rises 8% on US FDA approval for the Apremilast tablets
19.02.2021
Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug
02.02.2021
Unichem Labs Consolidated December 2020 Net Sales at Rs 326.28 crore, up 9.84% Y-o-Y
02.02.2021
Unichem Labs Standalone December 2020 Net Sales at Rs 311.18 crore, up 34.6% Y-o-Y
02.02.2021
Unichem Labs Consolidated December 2020 Net Sales at Rs 326.28 crore, up 9.84% Y-o-Y
02.02.2021
Unichem Labs Standalone December 2020 Net Sales at Rs 311.18 crore, up 34.6% Y-o-Y
03.11.2020
Unichem Labs Standalone September 2020 Net Sales at Rs 310.93 crore, up 38.13% Y-o-Y
03.11.2020
Unichem Labs Consolidated September 2020 Net Sales at Rs 317.51 crore, up 7.41% Y-o-Y
